Combination of YM155, a survivin suppressant with a STAT3 inhibitor: A new strategy to treat diffuse large B-cell lymphoma

Leukemia Research

Volumn 37, Issue 9, 2013, Pages 1156-1161

  Kaneko, Naoki ^a   Kita, Aya ^a   Yamanaka, Kentaro ^a   Mori, Masamichi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

DLBCL; Rituximab; STAT3; Survivin; YM155

Indexed keywords

ACTIN; ANTINEOPLASTIC AGENT; CELL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MYC PROTEIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHOPROTEIN; PHOSPHOPROTEIN P38; PHOSPHOPROTEIN STAT3; PROTEIN KINASE B; PROTEIN PARP; RITUXIMAB; SEPANTRONIUM BROMIDE; STA 21; STAT3 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL ASSAY; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE;

DLBCL; RITUXIMAB; STAT3; SURVIVIN; YM155;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; LYMPHOMA, LARGE B-CELL, DIFFUSE; NAPHTHOQUINONES; POLYCYCLIC COMPOUNDS; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 84880930111     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.05.010     Document Type: Article

References (37)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma The Non-Hodgkin's Lymphoma Classification Project. Blood 1997, 89:3909-3918.
2. Cheson B.D., Leonard J.P. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008, 359:613-626.
3. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
4. Hiddemann W., Kneba M., Dreyling M., Schmitz N., Lengfelder E., Schmits R., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725-3732.
5. Pfreundschuh M., Trumper L., Osterborg A., Pettengell R., Trneny M., Imrie K., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379-391.
6. Friedberg J.W. Relapsed/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program 2011, 2011:498-505.
7. Mita A.C., Mita M.M., Nawrocki S.T., Giles F.J. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008, 14:5000-5005.
8. Adida C., Haioun C., Gaulard P., Lepage E., Morel P., Briere J., et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000, 96:1921-1925.
9. Markovic O., Marisavljevic D., Cemerikic V., Perunicic M., Savic S., Filipovic B., et al. Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL). Eur J Haematol 2011, 86:246-255.
10. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-921.
11. Ansell S.M., Arendt B.K., Grote D.M., Jelinek D.F., Novak A.J., Wellik L.E., et al. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 2004, 18:616-623.
12. Nakahara T., Takeuchi M., Kinoyama I., Minematsu T., Shirasuna K., Matsuhisa A., et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007, 67:8014-8021.
13. Nakahara T., Kita A., Yamanaka K., Mori M., Amino N., Takeuchi M., et al. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci 2011, 102:614-621.
14. Kita A., Nakahara T., Yamanaka K., Nakano K., Nakata M., Mori M., et al. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leuk Res 2011.
15. Tolcher A.W., Mita A., Lewis L.D., Garrett C.R., Till E., Daud A.I., et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008, 26:5198-5203.
16. Cheson B.D., Bartlett N.L., Vose J.M., Lopez-Hernandez A., Seiz A.L., Keating A.T., et al. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer 2012, 118:3128-3134.
17. Darnell J.E. STATs and gene regulation. Science 1997, 277:1630-1635.
18. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., Schreiber R.D. How cells respond to interferons. Annu Rev Biochem 1998, 67:227-264.
19. Bromberg J.F., Horvath C.M., Besser D., Lathem W.W., Darnell J.E. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998, 18:2553-2558.
20. Turkson J., Bowman T., Garcia R., Caldenhoven E., De Groot R.P., Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1998, 18:2545-2552.
21. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., et al. Stat3 as an oncogene. Cell 1999, 98:295-303.
22. Yu H., Jove R. The STATs of cancer: new molecular targets come of age. Nat Rev Cancer 2004, 4:97-105.
23. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809.
24. Ding B.B., Yu J.J., Yu R.Y., Mendez L.M., Shaknovich R., Zhang Y., et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008, 111:1515-1523.
25. Scuto A., Kujawski M., Kowolik C., Krymskaya L., Wang L., Weiss L.M., et al. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res 2011, 71:3182-3188.
26. Vega M.I., Huerta-Yepaz S., Garban H., Jazirehi A., Emmanouilides C., Bonavida B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 2004, 23:3530-3540.
27. Meydan N., Grunberger T., Dadi H., Shahar M., Arpaia E., Lapidot Z., et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996, 379:645-648.
28. Song H., Wang R., Wang S., Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A 2005, 102:4700-4705.
29. Oliver F.J., de la Rubia G., Rolli V., Ruiz-Ruiz M.C., de Murcia G., Murcia J.M. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis, Lesson from an uncleavable mutant. J Biol Chem 1998, 273:33533-33539.
30. Suzuki E., Umezawa K., Bonavida B. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene 2007, 26:6184-6193.
31. Hailfinger S., Lenz G., Ngo V., Posvitz-Fejfar A., Rebeaud F., Guzzardi M., et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2009, 106:19946-19951.
32. Yap D.B., Chu J., Berg T., Schapira M., Cheng S.W., Moradian A., et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011, 117:2451-2459.
33. Shen Y., Devgan G., Darnell J.E., Bromberg J.F. Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc Natl Acad Sci U S A 2001, 98:1543-1548.
34. Aoki Y., Feldman G.M., Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003, 101:1535-1542.
35. Mankan A.K., Greten F.R. Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors. Expert Opin Investig Drugs 2011, 20:1263-1275.
36. Uddin S., Hussain A.R., Siraj A.K., Manogaran P.S., Al-Jomah N.A., Moorji A., et al. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006, 108:4178-4186.
37. Kita A., Mitsuoka K., Kaneko N., Nakata M., Miyoshi S., Jitsuoka M., et al. Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab. J Pharmacol Exp Ther 2012.